Gain: Reduction of Plasma Biomarker with Parkinson's Candidate

 Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function

Data presented at the International Congress of Parkinson's Disease and Movement Disorders^®

Gain remains on track to begin a Phase 1 clinical study of GT-02287 later this year

https://www.biospace.com/article/releases/gain-therapeutics-presents-new-preclinical-data-demonstrating-a-reduction-of-plasma-neurodegeneration-biomarker-nfl-after-administration-of-its-drug-candidate-gt-02287-in-gba1-parkinson-s-disease-model/